The journal of gene medicine · 2016
Application of HIF-1α by gene therapy enhances angiogenesis and osteogenesis in alveolar bone defect regeneration.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhang Yang, Huang Jiao, Wang Chao, Zhang Yan, Hu Changhong, Li Guangyue, Xu Ling
Аннотация
BACKGROUND: A successful clinical outcome for implanted tissue-engineered bone is dependent on the establishment of a functional vascular network. Gene-enhanced tissue engineering represents a promising approach for vascularization and osteogenesis. In the present study, we tested the angiogenesis and osteogenesis efficacy of gelatin as the scaffold carrier in combination with a virus encoding the HIF-1α gene in a rat alveolar bone defect model.
METHODS: Three groups of 10 rats each were either left untreated, treated with adenovirus encoding hypoxia-inducible factor-1α (AdHIF-1α)/gelatin sponge or treated with gelatin sponge with adenovirus encoding red fluorescence protein, respectively. At 4 weeks, all samples were determined by micro-computed tomography, histological analyses and immunohistochemical studies.
RESULTS: Scaffolds loaded with AdHIF-1α were able to sustain the release of AdHIF-1α for up to 21 days and alveolar bone defects treated with scaffolds containing AdHIF-1α significantly induced new bone and new vessel formation in vivo.
CONCLUSIONS: Overexpression of HIF-1α by gene therapy may be a useful method for enhancing alveolar bone defect osteogenesis and angiogenesis. Copyright © 2016 John Wiley & Sons, Ltd.
METHODS: Three groups of 10 rats each were either left untreated, treated with adenovirus encoding hypoxia-inducible factor-1α (AdHIF-1α)/gelatin sponge or treated with gelatin sponge with adenovirus encoding red fluorescence protein, respectively. At 4 weeks, all samples were determined by micro-computed tomography, histological analyses and immunohistochemical studies.
RESULTS: Scaffolds loaded with AdHIF-1α were able to sustain the release of AdHIF-1α for up to 21 days and alveolar bone defects treated with scaffolds containing AdHIF-1α significantly induced new bone and new vessel formation in vivo.
CONCLUSIONS: Overexpression of HIF-1α by gene therapy may be a useful method for enhancing alveolar bone defect osteogenesis and angiogenesis. Copyright © 2016 John Wiley & Sons, Ltd.